> Details

Buchhalter, Ivo; Rempel, Eugen; Endris, Volker; Allgäuer, Michael; Neumann, Olaf; Volckmar, Anna‐Lena; Kirchner, Martina; Leichsenring, Jonas; Lier, Amelie; von Winterfeld, Moritz; Penzel, Roland; Christopoulos, Petros; Thomas, Michael; Fröhling, Stefan; Schirmacher, Peter; Budczies, Jan; Stenzinger, Albrecht

Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
  • Contributor: Buchhalter, Ivo; Rempel, Eugen; Endris, Volker; Allgäuer, Michael; Neumann, Olaf; Volckmar, Anna‐Lena; Kirchner, Martina; Leichsenring, Jonas; Lier, Amelie; von Winterfeld, Moritz; Penzel, Roland; Christopoulos, Petros; Thomas, Michael; Fröhling, Stefan; Schirmacher, Peter; Budczies, Jan; Stenzinger, Albrecht
  • Published: Wiley, 2019
  • Published in: International Journal of Cancer, 144 (2019) 4, Seite 848-858
  • Language: English
  • DOI: 10.1002/ijc.31878
  • ISSN: 0020-7136; 1097-0215
  • Origination:
  • Footnote:
  • Description: Tumor mutational burden (TMB) represents a new determinant of clinical benefit from immune checkpoint blockade that identifies responders independent of PD‐L1 expression levels and is currently being explored in clinical trials. Although TMB can be measured directly by comprehensive genomic approaches such as whole‐genome and exome sequencing, broad availability, short turnaround times, costs and amenability to formalin‐fixed and paraffin‐embedded tissue support the use of gene panel sequencing for approximating TMB in routine diagnostics. However, data on the parameters influencing panel‐based TMB estimation are limited. Here, we report an extensive in silico analysis of the TCGA data set that simulates various panel sizes and compositions. We demonstrate that panel size is a critical parameter that influences confidence intervals (CIs) and cutoff values as well as important test parameters including sensitivity, specificity, and positive predictive value. Moreover, we evaluate the Illumina TSO500 panel, which will be made available for TMB estimation, and propose dynamic, entity‐specific cutoff values based on current clinical trial data. Optimizing the cost–benefit ratio, our data suggest that panels between 1.5 and 3 Mbp are ideally suited to estimate TMB with small CIs, whereas smaller panels tend to deliver imprecise TMB estimates for low to moderate TMB (0–30 muts/Mbp), connected with insufficient separation of hypermutated tumors from non‐hypermutated tumors.
  • Access State: Open Access